SCIENTIFIC EVIDENCE

Macro CD5L + deteriorates CD8 + T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.

Nature communications

Lu JC, Wu LL, Sun YN, Huang XY, Gao C, Guo XJ, Zeng HY, Qu XD, Chen Y, Wu D, Pei YZ, Meng XL, Zheng YM, Liang C, Zhang PF, Cai JB, Ding ZB, Yang GH, Ren N, Huang C, Wang XY, Gao Q, Sun QM, Shi YH, Qiu SJ, Ke AW, Shi GM, Zhou J, Sun YD, Fan J.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2024

Bioprocessing

Cancer Research

Immunology

Single-Cell Analysis

No items found.

Key Finding

The data provide a resource for predicting response of the combination therapy and highlight the importance of CD8 + T-cell status conversion and exhaustion induced by Macro CD5L + in influencing the response, suggesting future avenues for cancer treatment optimization.

Countstar Connection

Using Countstar Rigel S2, the study measured cell numbers in the study's cell samples during preparation for single-cell or single-nucleus analysis.

View paper ↗

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online